121 related articles for article (PubMed ID: 25730797)
41. The effect of lauryl capping group on protein release and degradation of poly(D,L-lactic-co-glycolic acid) particles.
Samadi N; Abbadessa A; Di Stefano A; van Nostrum CF; Vermonden T; Rahimian S; Teunissen EA; van Steenbergen MJ; Amidi M; Hennink WE
J Control Release; 2013 Dec; 172(2):436-43. PubMed ID: 23751568
[TBL] [Abstract][Full Text] [Related]
42. Dual growth factor delivery using biocompatible core-shell microcapsules for angiogenesis.
Choi DH; Subbiah R; Kim IH; Han DK; Park K
Small; 2013 Oct; 9(20):3468-76. PubMed ID: 23585380
[TBL] [Abstract][Full Text] [Related]
43. Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.
Yin J; Noda Y; Yotsuyanagi T
Int J Pharm; 2006 May; 314(1):46-55. PubMed ID: 16551494
[TBL] [Abstract][Full Text] [Related]
44. Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles.
Klose D; Delplace C; Siepmann J
Int J Pharm; 2011 Feb; 404(1-2):75-82. PubMed ID: 21056644
[TBL] [Abstract][Full Text] [Related]
45. Design and optimization of NSAID loaded nanoparticles.
Sashmal S; Mukherjee S; Ray S; Thakur RS; Ghosh LK; Gupta BK
Pak J Pharm Sci; 2007 Apr; 20(2):157-62. PubMed ID: 17416573
[TBL] [Abstract][Full Text] [Related]
46. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process.
Kempe S; Metz H; Mäder K
J Control Release; 2008 Sep; 130(3):220-5. PubMed ID: 18611421
[TBL] [Abstract][Full Text] [Related]
47. Bupivacaine-loaded biodegradable poly(lactic-co-glycolic) acid microspheres I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release.
Zhang H; Lu Y; Zhang G; Gao S; Sun D; Zhong Y
Int J Pharm; 2008 Mar; 351(1-2):244-9. PubMed ID: 18024022
[TBL] [Abstract][Full Text] [Related]
48. Thermally-triggered gelation of PLGA dispersions: towards an injectable colloidal cell delivery system.
Fraylich MR; Liu R; Richardson SM; Baird P; Hoyland J; Freemont AJ; Alexander C; Shakesheff K; Cellesi F; Saunders BR
J Colloid Interface Sci; 2010 Apr; 344(1):61-9. PubMed ID: 20070971
[TBL] [Abstract][Full Text] [Related]
49. In-situ forming implants for the treatment of periodontal diseases: Simultaneous controlled release of an antiseptic and an anti-inflammatory drug.
Lizambard M; Menu T; Fossart M; Bassand C; Agossa K; Huck O; Neut C; Siepmann F
Int J Pharm; 2019 Dec; 572():118833. PubMed ID: 31715363
[TBL] [Abstract][Full Text] [Related]
50. Cholesterol in situ forming gel loaded with doxycycline hyclate for intra-periodontal pocket delivery.
Phaechamud T; Setthajindalert O
Eur J Pharm Sci; 2017 Mar; 99():258-265. PubMed ID: 28027940
[TBL] [Abstract][Full Text] [Related]
51. Effect of implant formation on drug release kinetics of in situ forming implants.
Suh MS; Kastellorizios M; Tipnis N; Zou Y; Wang Y; Choi S; Burgess DJ
Int J Pharm; 2021 Jan; 592():120105. PubMed ID: 33232755
[TBL] [Abstract][Full Text] [Related]
52. Solvent exchange-induced in situ forming gel comprising ethyl cellulose-antimicrobial drugs.
Phaechamud T; Mahadlek J
Int J Pharm; 2015 Oct; 494(1):381-92. PubMed ID: 26302862
[TBL] [Abstract][Full Text] [Related]
53. An in vitro gel-based system for characterizing and predicting the long-term performance of PLGA in situ forming implants.
Li Z; Mu H; Weng Larsen S; Jensen H; Østergaard J
Int J Pharm; 2021 Nov; 609():121183. PubMed ID: 34653562
[TBL] [Abstract][Full Text] [Related]
54. Effect of polymer type on the dynamics of phase inversion and drug release in injectable in situ gelling systems.
Liu H; Venkatraman SS
J Biomater Sci Polym Ed; 2012; 23(1-4):251-66. PubMed ID: 21244721
[TBL] [Abstract][Full Text] [Related]
55. Cosolvent effects on the drug release and depot swelling in injectable in situ depot-forming systems.
Liu H; Venkatraman SS
J Pharm Sci; 2012 May; 101(5):1783-93. PubMed ID: 22318766
[TBL] [Abstract][Full Text] [Related]
56. Designing Solvent Exchange-Induced In Situ Forming Gel from Aqueous Insoluble Polymers as Matrix Base for Periodontitis Treatment.
Srichan T; Phaechamud T
AAPS PharmSciTech; 2017 Jan; 18(1):194-201. PubMed ID: 26951505
[TBL] [Abstract][Full Text] [Related]
57. Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?
Parent M; Boudier A; Dupuis F; Nouvel C; Sapin A; Lartaud I; Six JL; Leroy P; Maincent P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):640-9. PubMed ID: 23954508
[TBL] [Abstract][Full Text] [Related]
58. Poly(ethylene carbonate) as a surface-eroding biomaterial for in situ forming parenteral drug delivery systems: a feasibility study.
Liu Y; Kemmer A; Keim K; Curdy C; Petersen H; Kissel T
Eur J Pharm Biopharm; 2010 Oct; 76(2):222-9. PubMed ID: 20650316
[TBL] [Abstract][Full Text] [Related]
59. Effect of co-solvents on the controlled release of calcitonin polypeptide from in situ biodegradable polymer implants.
Prabhu S; Tran LP; Betageri GV
Drug Deliv; 2005; 12(6):393-8. PubMed ID: 16253955
[TBL] [Abstract][Full Text] [Related]
60. Effect of Polymer Permeability and Solvent Removal Rate on
Zhang X; Yang L; Zhang C; Liu D; Meng S; Zhang W; Meng S
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31658642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
